Lv58
1240 积分 2026-03-16 加入
Linking tumour angiogenesis and tumour immunity
4天前
已完结
The therapeutic window of antibody drug conjugates: A dogma in need of revision
4天前
已完结
Clinicopathologic features and prognosis of synchronous and metachronous multiple primary colorectal cancer
16天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
24天前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6
1个月前
已完结
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
1个月前
已完结
Elacestrant in metastatic breast cancer: current advancements and future perspectives
1个月前
已完结
Small Molecule‐Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs
1个月前
已完结
Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
1个月前
已完结
皖公网安备34019202002308
